Fresenius SE & Co. KGaA (XTRA: FRE)
Health Care · Health Care Providers & Services · DE
€45.85
+0.01% today · -3.1% 1Y
Fresenius SE & Co. KGaA (XTRA: FRE) operates in the Health Care Providers & Services industry within the Health Care sector. The company is valued at $30.13B and employs 178,486 people.
Over the last twelve months the share price has lost 3.1%, trading between 35.11 and 52.96.
Tweenvest scores Fresenius SE & Co. KGaA across four factors: quality 62/100, value 42/100, growth 25/100, dividend 61/100. Its strongest factor is quality.
FRE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $30.13B
- Revenue (TTM)
- $26.60B
- P/E
- 16.52
- EPS
- 2.70
- Dividend yield
- 2.28%
- Beta (5Y)
- 0.83
- 52-week high
- €52.96
- 52-week low
- €35.11
- Avg volume (3M)
- —
- Shares outstanding
- 563.24M
- Employees
- 178,486
- Next earnings
- —
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
- ISIN
- DE000FRE5EN2
- Founded
- 1912
- Listed since
- Nov 9, 1998
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Health Care Providers & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| UnitedHealth Group IncorporatedNYSE: UNH | $355.98B | $396.59 | -0.54% |
| CVS Health CorporationNYSE: CVS | $118.82B | $92.90 | -1.29% |
| McKesson CorporationNYSE: MCK | $105.52B | $905.09 | +3.58% |
| HCA Healthcare, Inc.NYSE: HCA | $92.83B | $428.76 | -0.11% |
| Elevance Health, Inc.NYSE: ELV | $86.50B | $398.87 | -0.93% |
| The Cigna GroupNYSE: CI | $73.81B | $279.32 | -0.40% |
| Cencora, Inc.NYSE: COR | $62.60B | $328.06 | +1.33% |
| Cardinal Health, Inc.NYSE: CAH | $55.33B | $237.92 | +2.39% |
Figures last refreshed Aug 18, 2026.